Bio Pharma Dive

JANUARY 31, 2023

The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.

Gene 306

Gene In-Vivo Gene Therapy Manufacturing 306

Bio Pharma Dive

MARCH 20, 2024

The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.

In-Vivo 189

In-Vivo 189

Pharmaceutical Technology

MARCH 21, 2024

Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.

In-Vivo 245

In-Vivo 245

Bio Pharma Dive

OCTOBER 3, 2023

The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

Gene Editing 264

Gene Editing In-Vivo Gene Genetics 264

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 264

Gene Editing Gene In-Vivo RNA 264

Pharmaceutical Technology

JULY 18, 2023

Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.

Genetics 246

Genetics In-Vivo Development Genomics 246

Bio Pharma Dive

JULY 17, 2023

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

Gene Editing 237

Gene Editing Gene In-Vivo Research 237

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.

In-Vivo 240

In-Vivo RNA Research Medicine 240

pharmaphorum

JUNE 28, 2021

So far, human trial data for gene-editing drugs have been generated for ex vivo therapies, meaning the CRISPR technology is used to modify cells outside the body, which are then reinfused into the patient. — Eric Topol (@EricTopol) June 26, 2021. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105

In-Vivo Gene Editing Trials Drugs 105

Scienmag

SEPTEMBER 28, 2020

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96

In-Vivo Research Engineer Medicine 96

Bio Pharma Dive

MARCH 14, 2024

The Swedish biotech will use the investment to advance a kind of personalized cancer therapy that reprograms tumor cells inside the body.

In-Vivo 140

In-Vivo 140

Bio Pharma Dive

OCTOBER 7, 2024

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

Gene Editing 195

Gene Editing In-Vivo Gene Medicine 195

BioSpace

JULY 10, 2024

Interius BioTherapeutics has received approval from Australia’s Human Research Ethics Committee to begin the first-in-human trial of an investigational in vivo CAR-T therapy designed to treat B-cell malignancies.

In-Vivo 74

In-Vivo Trials Research 74

BioSpace

JULY 19, 2021

Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.

In-Vivo 145

In-Vivo In-Vitro Drugs 145

pharmaphorum

OCTOBER 28, 2024

Discover the latest advancements in cell therapy with the next generation of innovative treatments that are revolutionising healthcare. Explore the future of medicine today.

In-Vivo 111

In-Vivo Medicine 111

Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Engineer Medicine 72

Bio Pharma Dive

DECEMBER 18, 2024

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.

In-Vivo 130

In-Vivo Drugs 130

Bio Pharma Dive

OCTOBER 25, 2023

The study results, while only from three participants, offer a glimpse at how one of the few in vivo CRISPR therapies in U.S. human testing is working.

Gene Editing 162

Gene Editing In-Vivo Gene 162

Pharmaceutical Technology

MAY 19, 2023

MT-302 is a TROP2-targeting in vivo chimeric antigen receptor (CAR) that has been designed to express in the myeloid compartment. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

Pharmaceutical Technology

APRIL 14, 2023

All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

pharmaphorum

MARCH 19, 2024

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52

In-Vivo Gene Editing Engineer Gene 52

Pharmaceutical Technology

NOVEMBER 22, 2022

In June last year, the company raised Series B funds worth $210m to advance its pipeline of in vivo engineered CAR T cell immunotherapies for treating solid tumours and hematologic malignancies into the clinic. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.

Development 276

Development In-Vivo Engineer Clinical Trials 276

Pharmaceutical Technology

MARCH 16, 2023

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge. The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

BioSpace

SEPTEMBER 29, 2021

EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.

In-Vivo 98

In-Vivo Gene 98

Pharmaceutical Technology

APRIL 26, 2024

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Gene Editing 130

Gene Editing Gene In-Vivo Development 130

BioSpace

MARCH 10, 2021

Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome.

In-Vivo 95

In-Vivo Genome Genomics Engineer 95

BioSpace

AUGUST 3, 2021

With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.

Gene Editing 132

Gene Editing In-Vivo Gene 132

Pharma Times

JANUARY 21, 2021

Antibodies in blood of vaccinated individuals neutralised in vivo version of variant

In-Vivo 123

In-Vivo Vaccination Vaccine Antibody 123

BioSpace

OCTOBER 21, 2021

The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.

In-Vivo 91

In-Vivo Drugs Development 91

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

XTalks

OCTOBER 9, 2024

Tune into the episode to learn more about the promise of in vivo CAR T therapy and novel advancements in the field. In this episode, Vera spoke with Tim Culp, PhD, Vice President of Research and Development at Interius BioTherapeutics, a Philadelphia-based biotech company.

In-Vivo 59

In-Vivo Life Science Doctors Doctor 59

BioSpace

JULY 6, 2021

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures.

Gene Editing 97

Gene Editing In-Vivo Gene Medicine 97

Pharmaceutical Technology

JANUARY 4, 2023

A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Pharmaceutical Technology

SEPTEMBER 19, 2022

A one-time gene therapy, Skysona leverages ex-vivo transduction with the Lenti-D lentiviral vector for adding the ABCD1 gene’s functional copies into the hematopoietic stem cells of the patient. The treatment is indicated for usage in boys aged four to 17 years with CALD. 1) in Skysona-treated and untreated subjects. thalassemia.

FDA Approval 246

FDA Approval In-Vivo Gene Therapy Clinical Trials 246

Pharma Mirror

FEBRUARY 18, 2021

Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.

Drug Delivery 130

Drug Delivery In-Vivo In-Vitro Drugs 130

BioPharma Reporter

JUNE 13, 2023

Sygnature Discovery has launched an in vivo inflammation model, that the company says is âexciting but only the beginningâ of understanding life-limiting neuroinflammatory conditions.

In-Vivo 52

In-Vivo Development 52

pharmaphorum

JANUARY 10, 2024

Precision BioSciences licenses non-cancer uses of its allogeneic CAR-T therapy azer-cel to TG Therapeutics as it pivots to in vivo applications of its gene-editing technology

Gene Editing 111

Gene Editing In-Vivo Licensing Licensing 111